Alvin Shih

Biography

Alvin Shih has served as the Chief Executive Officer of Enzyvant since November 2016. Prior to joining Enzyvant, Dr. Shih was the Chief Operating Officer for Rare Diseases at Pfizer, and the global head of R&D at Retrophin. Before joining biopharma, he was a healthcare consultant at LEK Consulting and McKinsey & Company. Dr. Shih holds an M.D. from the University of Alabama, an M.B.A. from Northwestern University, and completed his training in internal medicine at the Massachusetts General Hospital. Alvin Shih has served as the Chief Executive Officer of Enzyvant since November 2016. Prior to joining Enzyvant, Dr. Shih was the Chief Operating Officer for Rare Diseases at Pfizer, and the global head of R&D at Retrophin. Before joining biopharma, he was a healthcare consultant at LEK Consulting and McKinsey & Company. Dr. Shih holds an M.D. from the University of Alabama, an M.B.A. from Northwestern University, and completed his training in internal medicine at the Massachusetts General Hospital.

Research Interest

Pharmaceutical Analysis and Quality Assurance  Industrial Pharmacy Clinical Pharmacy  Pharmaceutical Administration Medicinal Chemistry  Drug Discovery and Development